{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T06:00:13Z","timestamp":1785304813311,"version":"3.55.0"},"reference-count":48,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["SEBCATP\u20102023\/100009"],"award-info":[{"award-number":["SEBCATP\u20102023\/100009"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cancer\u2010associated cachexia is a complex, multistage metabolic disorder that markedly contributes to morbidity and mortality in patients with advanced cancer, yet effective pharmacological interventions are lacking. Cachexia drug development has expanded significantly in recent years, with multiple repurposed agents and novel therapies targeting specific pathways entering clinical trials. However, clinical benefit has been limited not only by a lack of promising agents but also, to a large extent, by suboptimal trial design.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Recent Findings<\/jats:title>\n                    <jats:p>This article reviews the current evidence to highlight the core principles required to modernize cachexia clinical trials. We emphasize that both repurposed drugs and novel agents have a role, but multimodal approaches integrating pharmacologic intervention with nutritional support and exercise are essential for therapeutic success. Early intervention, guided by predictive biomarkers such as C\u2010reactive protein and Interleukin\u20106, and relatively short study durations focused on rapid clinical benefit are critical considerations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>We demonstrate the importance of moving beyond weight\u2010based endpoints alone toward functional primary endpoints. Selection of appropriate control arms is crucial and should include multimodal interventions, while trial designs must account for patient heterogeneity and concurrent anticancer therapies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cnr2.70613","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T06:46:50Z","timestamp":1782974810000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design"],"prefix":"10.1002","volume":"9","author":[{"given":"Nada O.","family":"Othman","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadir","family":"Habib","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Cairo University  Cairo Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa M.","family":"Almeldin","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Cairo University  Cairo Egypt"},{"name":"Department of Oncology University College London  London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8627-3605","authenticated-orcid":false,"given":"Kyrillus S.","family":"Shohdy","sequence":"additional","affiliation":[{"name":"School of Cancer Sciences University of Glasgow  Glasgow UK"},{"name":"CRUK Scotland Institute  Glasgow UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"e_1_2_14_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nut.2019.06.020"},{"key":"e_1_2_14_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3829"},{"key":"e_1_2_14_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255-024-01167-9"},{"key":"e_1_2_14_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70218-7"},{"key":"e_1_2_14_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02232-8"},{"key":"e_1_2_14_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09502-0"},{"key":"e_1_2_14_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygcen.2024.114513"},{"key":"e_1_2_14_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2012.06.011"},{"key":"e_1_2_14_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/nn0703-655"},{"issue":"4","key":"e_1_2_14_11_1","first-page":"1432","article-title":"Role of the Central Melanocortin System in Cachexia","volume":"61","author":"Marks D. L.","year":"2001","journal-title":"Cancer Research"},{"key":"e_1_2_14_12_1","doi-asserted-by":"publisher","DOI":"10.4103\/2277-9175.179182"},{"key":"e_1_2_14_13_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7033"},{"key":"e_1_2_14_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpainsymman.2021.05.017"},{"issue":"3","key":"e_1_2_14_15_1","article-title":"Megestrol Acetate for Treatment of Anorexia\u2010Cachexia Syndrome","volume":"2013","author":"Ruiz Garcia V.","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_14_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13500"},{"key":"e_1_2_14_17_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01997"},{"key":"e_1_2_14_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-009-0739-7"},{"key":"e_1_2_14_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.schres.2008.09.025"},{"key":"e_1_2_14_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01280"},{"key":"e_1_2_14_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00558-6"},{"key":"e_1_2_14_22_1","unstructured":"EMA \u201cRefusal of the Marketing Authorisation for Adlumiz (Anamorelin Hydrochloride): European Medicines Agency \u201d (2017) https:\/\/www.ema.europa.eu\/en\/documents\/smop\u2010initial\/questions\u2010and\u2010answers\u2010refusal\u2010marketing\u2010authorisation\u2010adlumiz\u2010anamorelin\u2010hydrochloride_en.pdf."},{"key":"e_1_2_14_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08305-z"},{"key":"e_1_2_14_24_1","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.CRC-24-0565"},{"key":"e_1_2_14_25_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-4258"},{"key":"e_1_2_14_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2023.2194489"},{"key":"e_1_2_14_27_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_389942"},{"key":"e_1_2_14_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.e15195"},{"key":"e_1_2_14_29_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13434"},{"key":"e_1_2_14_30_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14555-5"},{"key":"e_1_2_14_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13491"},{"key":"e_1_2_14_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clnu.2008.06.013"},{"key":"e_1_2_14_33_1","doi-asserted-by":"publisher","DOI":"10.1139\/H08-075"},{"key":"e_1_2_14_34_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2018.0137"},{"key":"e_1_2_14_35_1","doi-asserted-by":"publisher","DOI":"10.1097\/SPC.0b013e328331124a"},{"key":"e_1_2_14_36_1","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2024.14860"},{"key":"e_1_2_14_37_1","doi-asserted-by":"publisher","DOI":"10.5535\/arm.21106"},{"key":"e_1_2_14_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00520-026-10614-0"},{"key":"e_1_2_14_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-024-03502-8"},{"key":"e_1_2_14_40_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.720096"},{"key":"e_1_2_14_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13453"},{"key":"e_1_2_14_42_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e8668"},{"key":"e_1_2_14_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100092"},{"key":"e_1_2_14_44_1","unstructured":"A.Walling T.Campbell andR.Agarwal \u201cNCCN Clinical Practice Guidelines in Oncology: Palliative Care. Version 2.2025. NCCN \u201d (2025)."},{"key":"e_1_2_14_45_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2025.7117"},{"key":"e_1_2_14_46_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040655"},{"issue":"18","key":"e_1_2_14_47_1","first-page":"4009","article-title":"The Role of Interleukin\u20106 Family Cytokines in Cancer Cachexia","volume":"291","author":"Agca S.","year":"2024","journal-title":"FEBS Journal"},{"key":"e_1_2_14_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcsm.13435"},{"issue":"3","key":"e_1_2_14_49_1","article-title":"Multimodal Interventions for Cachexia Management","volume":"3","author":"Reid J.","year":"2025","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cnr2.70613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T05:14:18Z","timestamp":1785302058000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":48,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["10.1002\/cnr2.70613"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70613","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"value":"2573-8348","type":"print"},{"value":"2573-8348","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"2026-02-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-12","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70613"}}